[go: up one dir, main page]

CN114929703A - 一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法 - Google Patents

一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法 Download PDF

Info

Publication number
CN114929703A
CN114929703A CN202180008525.8A CN202180008525A CN114929703A CN 114929703 A CN114929703 A CN 114929703A CN 202180008525 A CN202180008525 A CN 202180008525A CN 114929703 A CN114929703 A CN 114929703A
Authority
CN
China
Prior art keywords
formula
compound
xrpd
pattern
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180008525.8A
Other languages
English (en)
Other versions
CN114929703B (zh
Inventor
徐文卫
单振良
张迎亚
张国亮
戈云
张爱明
张喜全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Pharmaceutical Holdings Beijing Co ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Capital Pharmaceutical Holdings Beijing Co ltd
Publication of CN114929703A publication Critical patent/CN114929703A/zh
Application granted granted Critical
Publication of CN114929703B publication Critical patent/CN114929703B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一种式(I)所示的溴区结构域蛋白抑制剂的晶型、盐型及其制备方法，以及上述晶型和盐型在制备治疗由BET蛋白介导的疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN202180008525.8A 2020-01-19 2021-01-19 一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法 Active CN114929703B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020100601102 2020-01-19
CN202010060110 2020-01-19
CN2020100572970 2020-01-19
CN202010057297 2020-01-19
PCT/CN2021/072651 WO2021143922A1 (zh) 2020-01-19 2021-01-19 一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法

Publications (2)

Publication Number Publication Date
CN114929703A true CN114929703A (zh) 2022-08-19
CN114929703B CN114929703B (zh) 2025-03-28

Family

ID=76864750

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180008525.8A Active CN114929703B (zh) 2020-01-19 2021-01-19 一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法

Country Status (5)

Country Link
US (1) US20240101551A1 (zh)
EP (1) EP4092027A4 (zh)
JP (1) JP2023510610A (zh)
CN (1) CN114929703B (zh)
WO (1) WO2021143922A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024230727A1 (zh) * 2023-05-09 2024-11-14 正大天晴药业集团股份有限公司 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018130174A1 (zh) * 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
AR096758A1 (es) * 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
CN110577526B (zh) * 2018-06-07 2023-10-27 上海翰森生物医药科技有限公司 溴域结构蛋白抑制剂的盐及其制备方法和应用
CN112424200B (zh) * 2018-07-25 2022-09-20 正大天晴药业集团股份有限公司 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018130174A1 (zh) * 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
WO2021143922A1 (zh) 2021-07-22
CN114929703B (zh) 2025-03-28
EP4092027A4 (en) 2024-02-14
US20240101551A1 (en) 2024-03-28
EP4092027A1 (en) 2022-11-23
JP2023510610A (ja) 2023-03-14

Similar Documents

Publication Publication Date Title
CN113717157B (zh) 用作cdk7激酶抑制剂的化合物及其应用
CN107922425B (zh) 制备parp抑制剂、结晶形式的方法及其用途
CN109689641B (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
CA3170068A1 (en) Spiro ring-containing quinazoline compound
EP2947086B1 (en) Novel fused pyrimidine compound or salt thereof
EP2949647B1 (en) Deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing same
AU2020208272A1 (en) Salt of EGFR inhibitor, crystal form, and preparation method therefor
CN114929701B (zh) 一种pde3/pde4双重抑制剂的结晶及其应用
JP2025511974A (ja) がんの治療のためのラクテート／ＡＴＰ産生阻害剤としてのＮ－（３－（ベンゾ［ｂ］チオフェン－２－カルボキシアミド）－フェニル）－２，３－ジヒドロベンゾ［ｂ］［１，４］ジオキシン－６－カルボキシアミド誘導体及び関連化合物
CA3221997A1 (en) Compound as cdk kinase inhibitor and use thereof
US20240350501A1 (en) SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT
TWI723480B (zh) 用作fgfr4抑制劑的稠環衍生物
CN114929703A (zh) 一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法
CN117797146A (zh) Sarm1酶活性抑制剂及其在神经退行性疾病中的应用
WO2025051211A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
WO2024061172A1 (zh) 一种脯氨酰羟化酶抑制剂及其用途
CN114853762A (zh) 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
WO2022247885A1 (zh) 三并杂环类化合物的结晶和盐及其应用
EP4116300A1 (en) Crystal of tricyclic compound acting on crbn protein and preparation method therefor
CN111333655A (zh) 一种三唑并嘧啶类化合物及其制备方法和应用
CN110078732A (zh) 嘌呤类化合物及其用途
HK40085080A (zh) 一种pde3/pde4双重抑制剂的结晶及其应用
WO2023202706A1 (zh) 硒杂环类化合物的盐型和晶型及其应用
JP2025515208A (ja) 多環式化合物およびその使用
CN121226368A (zh) Ripk1抑制剂及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant